NA
TRIB

Navellier & Associates’s Trinity Biotech TRIB Stock Holding History

Navellier & Associates’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-103
Closed -$33K – 350
2021
Q3 		$33K Sell
103
-568
-85% -$200K 0.01% 308
2021
Q2 		$296K Buy
671
+126
+23% +$62.9K 0.04% 250
2021
Q1 		$307K Buy
545
+112
+26% +$80.8K 0.06% 231
2020
Q4 		$248K Buy
+433
New +$215K 0.04% 245

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Navellier & Associates's TRIB Position: Q4 2021 in Review

Navellier & Associates sold out of Trinity Biotech (TRIB) in Q4 2021, closing a stake of 103 shares — an estimated $33K sold.

Navellier & Associates first reported a position in TRIB in Q4 2020 and held it in 4 quarters. The position peaked at $307K in Q1 2021. 20 funds tracked by Wall St. Rank hold TRIB as of Q4 2021.

  • Navellier & Associates reported no remaining Trinity Biotech position as of Q4 2021 after selling out during the quarter.
  • Navellier & Associates sold 103 Trinity Biotech shares in Q4 2021, an estimated $33K.
  • Navellier & Associates first reported a position in Trinity Biotech in Q4 2020 and held it in 4 quarters.
  • Navellier & Associates's Trinity Biotech position peaked at $307K in Q1 2021.
  • 20 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2021.

Based on Navellier & Associates's 13F filing for Q4 2021, filed 14 Feb 2022.